An observational study in Severe Combined Immunodeficiency (SCID), Leaky SCID and Omenn Syndrome, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Enrolling by invitation at 44 sites in 2 countries. Per ClinicalTrials.gov, last updated 2020-11-10.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Severe Combined Immunodeficiency with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Severe Combined Immunodeficiency · United States.
Among the 38 studies in Severe Combined Immunodeficiency with a site in United States, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2010, is one of 12 observational ones, and was the 21st registered.
59 studies on the registry are indexed under Severe Combined Immunodeficiency; 14 are open to participants now.
Browse Severe Combined Immunodeficiency studies →9 of the 38 studies in Severe Combined Immunodeficiency with a site in United States are open now. Recruiting first, the newest first:
Paul Szabolcs · Sites in United States
Ages 5–40
Paul Szabolcs · Sites in United States
Ages 2 mo–60 yrs
University of California, San Francisco · Sites in United States
Ages 2 mo+
Paul Szabolcs · Sites in United States
Ages 2 mo–55 yrs
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 6 mo–99 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Severe Combined Immunodeficiency studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 16 · Phase 3 3
First in 1990; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 690 is above the median of 100 across 19 observational studies indexed under Severe Combined Immunodeficiency.
Median enrollment 9 across the 24 interventional studies, 88 across the 12 observational. Of the 24 that completed or were terminated, 10 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 38 have an industry lead sponsor. The 10 most frequent:
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.
National Institute of Allergy and Infectious Diseases (NIAID) has 5 studies filed under Severe Combined Immunodeficiency — fewer than ten, so there is no comparison to draw.
3 of the studies in Severe Combined Immunodeficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01852370Paul SzabolcsSequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases | 2026-11 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT03597594St. Jude Children's Research HospitalHaplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Severe Combined Immunodeficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective evaluation of children with Severe Combined Immune Deficiency (SCID) who are treated under a variety of protocols used by participating institutions. In order to determine the patient, recipient and transplant-related variables that are most important in determining outcome, study investigators will uniformly collect pre-, post- and peri-transplant (or other treatment) information on all children enrolled into this study.
Children will be divided into three strata:
Each Group/Cohort Stratum will be analyzed separately.
This study follows participants with SCID prospectively, meaning the study enrolls participants where there is a plan to receive a blood and marrow transplant, enzyme therapy, or gene therapy in the future. Participants are then followed according to a schedule set out by the study protocol after the procedure. There are no experimental therapies on this study.
The goal of this study is to learn more about: (1) outcomes from the treatment of SCID in the modern era of medicine (2) what factors lead to the best long-term outcomes, such as best donor, conditioning regimen, timing of transplant, etc., and (3) what impact newborn screening and the early diagnosis of SCID has had on the long-term outcomes following BMT or gene therapy. Information is also being gathered on how and when the immune system recovers after bone marrow transplant (BMT), quality of life for long-term survivors, and about whether children develop normally after treatment.
This natural history study is the largest coordinated prospective study of participants with SCID ever performed. Information that investigators will learn, both now and in the future, will help doctors and other health professionals to better treat children with SCID.
Patients with SCID spectrum disorders that have undergone diagnostic workup per local center practice and referred for enrollment in this natural history study at one of the participating institutions (clinical research site locations).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Stratum A: Typical SCID (formerly referred to as Classic SCID)- -Subjects who meet the following inclusion criteria and the intention is to treat with hematopoietic cell transplant (HCT) are eligible for enrollment into Stratum A (Typical SCID) of the study:
Stratum B: Leaky SCID, Omenn Syndrome, Reticular Dysgenesis-
-Subjects who meet the following criteria and the intention is to treat with HCT are eligible for enrollment into Stratum B:
Leaky SCID:
Either one or both of the following (a,b) :
AND at least two of the following (a through e):
a.) Reduced number of CD3 T cells
b.) ≥80% of CD3+ or CD4+ T cells that are 5RO+
Omenn Syndrome:
Maternal lymphocytes tested for and not detected;
--Note: If maternal engraftment was not assessed and ruled out, the subject is not eligible as Omenn Syndrome.
≥80% of CD3+ or CD4+ T cells are CD45RO+ AND/OR
NOTE: If proliferation to antigen was not performed, but at least 4 of the following 9 supportive criteria, at least one of which must be among those marked with an asterisk (*) below are present, the subject is eligible as Omenn Syndrome:
Reticular Dysgenesis:
≥2 of the following (a,b,c):
Stratum C:
Subjects who meet the following criteria and the intention is to treat with therapy other than allogeneic HCT, primarily PEG-ADA ERT or gene therapy with autologous modified (gene transduced) cells, are eligible for enrollment into
Stratum C:
Exclusion Criteria:
-Subjects who meet any of the following exclusion criteria are disqualified from enrollment in Strata A, B, or C of the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stratum A: Typical Severe Combined Immunodeficiency (SCID) treated with HCT therapy. Participants with typical (formerly referred to as classic) SCID + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol.
Stratum B: Atypical Severe Combined Immunodeficiency (SCID) treated with HCT therapy. Participants with leaky SCID, Omenn syndrome, or Reticular Dysgenesis (RS) + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol.
Stratum C: Severe Combined Immunodeficiency (SCID) who receive alternative therapy per standard of care, non-standard care and/or investigational. This stratum includes: * Adenosine Deaminase-Deficient SCID (ADA Deficient SCID) with intention to treat with Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT) * ADA Deficient SCID with intention to treat with gene therapy * X-linked SCID (XSCID) with intention to treat with gene therapy * Any individual with SCID previously treated with a thymus transplant (includes intention to treat with HCT, as well as PEG-ADA ERT or gene therapy)
Overall Survival (OS) at Month 6 Post HCT
Assess the overall survival (OS) for participants after hematopoietic stem cell transplantation (HCT) for treatment of Severe Combined Immunodeficiency (SCID). The time to this event is the time from HCT to death or last follow-up (whichever occurs first). All participants will be followed for a minimum of 6 months from HCT. Overall survival will be estimated at 6 months.
Time frame: Month 6 Post HCT
Overall Survival (OS) at Year 2 Post HCT
Assess the overall survival (OS) for participants after hematopoietic stem cell transplantation (HCT) for treatment of Severe Combined Immunodeficiency (SCID). The time to this event is the time from HCT to death or last follow-up (whichever occurs first). All participants will be followed for a minimum of 6 months from HCT. Overall survival will be estimated at 2 years.
Time frame: Year 2 Post HCT
Overall Survival (OS) at Year 5 Post HCT
Assess the overall survival (OS) for participants after hematopoietic stem cell transplantation (HCT) for treatment of Severe Combined Immunodeficiency (SCID). The time to this event is the time from HCT to death or last follow-up (whichever occurs first). All participants will be followed for a minimum of 6 months from HCT. Overall survival will be estimated at 5 years.
Time frame: Year 5 Post HCT
Overall Survival (OS) at Year 8 Post HCT
Assess the overall survival (OS) for participants after hematopoietic stem cell transplantation (HCT) for treatment of Severe Combined Immunodeficiency (SCID). The time to this event is the time from HCT to death or last follow-up (whichever occurs first). All participants will be followed for a minimum of 6 months from HCT. Overall survival will be estimated at 8 years.
Time frame: Year 8 Post HCT
T Cell Reconstitution by Stratum-Month 6, Year 2, Year 5 and Year 8 Post-SCID Treatment
A measure of immune reconstitution defined by the presence of three out of four of: 1. Lymphocyte proliferation to PHA ≥50% of lower limit of normal control 2. Total CD3+ \> 1000 / microliter 3. Total CD4+ \> 500 / microliter 4. Total CD4+ CD45RA+ \> 200 / microliter AND, for participants who received allogeneic HCT: -Donor T cell chimerism ≥80%
Time frame: From SCID Treatment (HCT, ERT or GT) to Month 6, Year 2, Year 5 and Year 8 Post-SCID Treatment
B Cell Reconstitution by Stratum-Month 6, Year 2, Year 5 and Year 8 Post-SCID Treatment
A measure of immune reconstitution defined by: -Intravenous Immunoglobulin (IVIG) independence and at least three of the following: 1. Normal IgA and IgM levels for age 2. Normal IgG levels for age, independent of supplemental gammaglobulin 3. Isohemagglutinins ≥1:8 4. Specific antibody production while off IVIG
Time frame: From SCID Treatment (HCT, ERT or GT) to Month 6, Year 2, Year 5 and Year 8 Post-SCID Treatment
Engraftment at Day 100, Month 6, Year 2, Year 5 and Year 8 Post-HCT
Whole-blood engraftment and engraftment in T-, B-, or Natural Killer (NK)-cell subsets will be assessed. For whole blood and subsets\*, the following engraftment criteria will be used: * \< 5% donor = autologous reconstitution * 5-80% donor = mixed chimerism * ≥ 80% donor = full chimerism * Subsets: * CD3 * CD19 * CD14 and/or CD15 (myeloid cells) * CD3- CD56+ NK cells Outcome analysis restricted to participants with hematopoietic (stem) cell transplantation (HCT) intervention.
Time frame: From HCT to Month 6, Year 2, Year 5 and Year 8 Post-HCT
Time to Resolution of Infections Diagnosed Prior to HCT
Time to resolution of any "pre-HCT" infections-bacterial, viral or fungal. Participants who are alive without resolving their pre-HCT infections will be considered censored at last contact. Resolution of pre-existing infection defined by: * Participant being clinically well, * Participant off treatment for infection(s), and/or * Negative culture/PCR assay. Outcome analysis restricted to participants with pre-hematopoietic (stem) cell transplantation (HCT) opportunistic infections.
Time frame: Through study completion, up to 8 years post-HCT
Incidence of New Infections Post-HCT
The occurrence of new documented bacterial, viral, or fungal infections-by site of disease, organism, date of onset, and resolution- post-HCT. Participants who are alive without infection will be considered censored at last contact. Outcome analysis restricted to participants with hematopoietic (stem) cell transplantation (HCT).
Time frame: From HCT to Day 100, Month 6, Year 1, Year 2, Year 5, and Year 8 post-HCT
Proportion of Participants Achieving Normal Nutritional Status Post-HCT
Normal nutrition status defined by: * Absence of chronic diarrhea and/or * No longer requiring supplemental nutrition (i.e., tube feeding or TPN). * TPN: total parenteral nutrition Outcome analysis restricted to participants with hematopoietic (stem) cell transplantation (HCT) intervention.
Time frame: Baseline (Pre-HCT) to Year 1, Year 2, Year 5 and Year 8 Post-HCT
Longitudinal Analysis: Growth Percentile in Body Height
Participant's height will be superimposed against gender specific standard growth charts.
Time frame: Baseline (Pre-HCT), Year 1, Year 2, Year 5 and Year 8 Post-HCT
Longitudinal Analysis: Growth Percentile in Body Weight
Participant's weight will be superimposed against gender specific standard growth charts.
Time frame: Baseline (Pre-HCT), Year 1, Year 2, Year 5 and Year 8 Post-HCT
Incidence of Acute Graft Versus Host Disease (GVHD) Post-HCT
Occurrence of acute GVHD. Any skin, gastrointestinal or liver abnormalities fulfilling the consensus criteria of Grades II-IV acute GVHD or grades III-IV acute GVHD are considered events. Participants alive without acute GVHD will be censored at the time of last follow-up. Outcome analysis restricted to participants with hematopoietic (stem) cell transplantation (HCT) intervention.
Time frame: From HCT to Day 100 and Month 6 post-HCT
Incidence of Chronic Graft Versus Host Disease (GVHD) Post-HCT
Occurrence of chronic GVHD in any organ system fulfilling the criteria of limited or extensive chronic GVHD. Participants alive without chronic GVHD will be censored at time of last follow-up. Outcome analysis restricted to participants with hematopoietic (stem) cell transplantation (HCT).
Time frame: From HCT to Month 6, Year 1,Year 2, Year 5 and Year 8 Post-HCT
Incidence of Autoimmunity Requiring Treatment by Stratum- Month 6, Year 2, Year 5 and Year 8 Post-SCID Treatment
Occurrence of autoimmunity requiring treatment with immunosuppression or other therapy. Participants alive without autoimmunity will be censored at time of last follow-up. Date of onset and type of treatment will be collected on: * Autoimmune hypothyroidism * Autoimmune cytopenia (hemolytic anemia, thrombocytopenia, neutropenia) * Arthritis * Myositis * Nephritis * Bronchiolitis obliterans or other pulmonary autoimmune disease * Vitiligo * Alopecia * Inflammatory bowel disease * Neurodegeneration * Vasculitis
Time frame: From SCID Treatment (HCT, ERT or GT) to Month 6, Year 2, Year 5 and Year 8 Post-SCID Treatment
Infant Neurocognitive Development By Stratum Measured by Bayley's Scales for Infant Development 3rd edition (BSID-III-R)
Infant development as measured by Bayley's scales for infant development 3rd edition (BSID-III-R, Bayley, 2006).\] The BSID III-R is a standardized developmental exam that is normalized to the age of the child in months. The mean adjusted score is 100 with a standard deviation of 15 (higher being better). Evaluation conducted as per standard of care in participants ≤30 months of age.
Time frame: Baseline (Pre-SCID Treatment-HCT, ERT or GT),Year 1, Year 2, Year 4, Year 5 and Year 8 Post-SCID Treatment
Neurocognitive Development By Stratum Measured by Vineland Adaptive Behavior Scales, Second Edition (Vineland II)
The Vineland II measures the personal and social skills of individuals from birth through adulthood. Since adaptive behavior refers to an individual's typical performance of the day-to-day activities required for personal and social sufficiency, these scales assess what a person actually does, rather than what he or she is able to do. Summary: The Vineland II is a measure of adaptive behavior in children, adolescents and adults. It yields an overall standard score (Adaptive Behavior Composite, ABC) and age standard scores in four domains: Communication, Daily Living Skills, Motor Skills, and Maladaptive Behaviour Index. ABC scores have a mean of 100 and a standard deviation of 15 (range = 20 to 160). Higher scores suggest a higher level of adaptive functioning. A rise in standard scores from Baseline indicates improvement. Evaluation as per standard of care.
Time frame: Baseline (Pre-SCID Treatment-HCT, ERT or GT),Year 1, Year 2, Year 4, Year 5 and Year 8 Post-SCID Treatment
Neurocognitive Development By Stratum Measured by Wechsler Preschool and Primary Intelligence Scale of Intelligence, Third Edition (WPPSI III)
Cognitive ability assessed using the WPPSI III. The WPPSI-III has been developed and standardized for children ages 2 years, 6 months through 7 years, 3 months of age. The WPPSI-III yields a Verbal Score, a Performance Score, a General Language Score, and a Full Scale Score. These scores have a mean of 100 and a standard deviation of 15. The range of possible values is 50 (worst value) to 150 (best value). Evaluation as per standard of care.
Time frame: Baseline (Pre-SCID Treatment-HCT, ERT or GT),Year 1, Year 2, Year 4, Year 5 and Year 8 Post-SCID Treatment
Neurocognitive Assessment by Stratum Using the Wechsler Intelligence Scale for Children, Fourth Edition (WISC-IV)
The WISC-IV is designed for children 6 years 0 months to 16 years 11 months. The Full Scale IQ, ranges from 45 to 155 with a mean of 100 and standard deviation of 15. Higher scores indicate stronger cognitive function. Scores between 90 and 110 are considered to be within the range of average IQ. Evaluation in accordance with standard of care, participant ages 6 years and above.
Time frame: Baseline (Pre-SCID Treatment-HCT, ERT or GT),Year 1, Year 2, Year 4, Year 5 and Year 8 Post-SCID Treatment
Incidence of Complications of HCT Requiring Treatment
Occurrence of health event(s) classified as an HCT treatment complication, including but not limited to: * Veno-occlusive disease * Thrombotic thrombocytopenic purpura * Bronchiolitis obliterans / chronic lung disease * Seizures * Hypertension Outcome analysis restricted to participants with hematopoietic (stem) cell transplantation (HCT) intervention.
Time frame: From HCT to Month 6, Year 1,Year 2, Year 5 and Year 8 Post-HCT
Comparison of Quality of Life (QOL) By Stratum Prior to and After SCID Treatment: Scores for Pediatric Quality of Life Questionnaire (Peds-QL)
The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, \& school functioning) are scored.
Time frame: Baseline (Pre-SCID Treatment-HCT, ERT or GT) to Year 1, Year 2, Year 4, Year 5 and Year 8 Post-SCID Treatment
Started Sep 2010 (actual). Primary completion is estimated for Sep 2028, 216 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Severe Combined Immunodeficiency →
National Institute of Allergy and Infectious Diseases (NIAID) →